optivate 1000 i.u
kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 1000 iu/vial; von willebrand factor 2600 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).
recombinate antihaemophilic factor 250 iu international unit pdr+solv for soln for inj
baxter healthcare limited - factor viii, human recombinant - pdr+solv for soln for inj - 250 iu international unit
recombinate antihaemophilic factor 500 iu international unit pdr+solv for soln for inj
baxter healthcare limited - factor viii, human recombinant - pdr+solv for soln for inj - 500 iu international unit
recombinate 1000 iu, powder and solvent for solution for injection
baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 1000 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease
recombinate 500 iu, powder and solvent for solution for injection
baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 500 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease.
recombinate 250 iu, powder and solvent for solution for injection
baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 250 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease.
coagadex
bpl bioproducts laboratory gmbh - human coagulation factor x - factor x deficiency - vitamin k and other hemostatics, antihemorrhagics, coagulation factor x - coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor x deficiency. coagadex is indicated in all age groups.
aleviate human coagulation factor viii 1000iu/ von willebrand factor 2400iu powder for injection vial with diluent vial
csl behring australia pty ltd - factor viii, quantity: 1000 iu; von willebrand factor, quantity: 2400 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.
aleviate human coagulation factor viii 500iu/ von willebrand factor 1200iu powder for injection vial with diluent vial
csl behring australia pty ltd - factor viii, quantity: 500 iu; von willebrand factor, quantity: 1200 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.
aleviate human coagulation factor viii 250iu / von willebrand factor 600iu powder for injection vial with diluent vial
csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 600 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.